RELV vs. ME, IBIO, GLYC, AEON, OBSV, ORGS, AEZS, CPHI, NRBO, and MTNB
Should you be buying Reliv' International stock or one of its competitors? The main competitors of Reliv' International include 23andMe (ME), iBio (IBIO), GlycoMimetics (GLYC), AEON Biopharma (AEON), ObsEva (OBSV), Orgenesis (ORGS), Aeterna Zentaris (AEZS), China Pharma (CPHI), NeuroBo Pharmaceuticals (NRBO), and Matinas Biopharma (MTNB).
Reliv' International vs. Its Competitors
23andMe (NASDAQ:ME) and Reliv' International (NASDAQ:RELV) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.
In the previous week, 23andMe had 12 more articles in the media than Reliv' International. MarketBeat recorded 12 mentions for 23andMe and 0 mentions for Reliv' International. 23andMe's average media sentiment score of 0.51 beat Reliv' International's score of 0.00 indicating that 23andMe is being referred to more favorably in the media.
23andMe has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Reliv' International has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500.
36.1% of 23andMe shares are owned by institutional investors. Comparatively, 8.0% of Reliv' International shares are owned by institutional investors. 26.3% of 23andMe shares are owned by insiders. Comparatively, 31.2% of Reliv' International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Reliv' International has lower revenue, but higher earnings than 23andMe.
Reliv' International has a net margin of -0.61% compared to 23andMe's net margin of -183.39%. Reliv' International's return on equity of -1.89% beat 23andMe's return on equity.
Summary
23andMe beats Reliv' International on 7 of the 13 factors compared between the two stocks.
Get Reliv' International News Delivered to You Automatically
Sign up to receive the latest news and ratings for RELV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RELV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reliv' International Competitors List
Related Companies and Tools
This page (NASDAQ:RELV) was last updated on 7/5/2025 by MarketBeat.com Staff
